219mze 发表于 2024-5-23 00:00:12

癌症疫苗最新动态：3年后仍存在免疫反应！

<img src="https://mmbiz.qpic.cn/sz_mmbiz_gif/Lkw2iaE07M9VGl240HN1UR5tUO8qrzkA44F2wy21t8QRY7ialNrScBGQDTXsIaqkX07DJ7notXWWZictyU6ku2aIQ/640?wx_fmt=gif&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"><span style="color: black;"><span style="color: black;"><span style="color: black;">近期</span>，BioNtech<span style="color: black;">颁布</span>了其个体化癌症疫苗autogene&nbsp;cevumeran</span><span style="color: black;">（BNT122，RO7198457）</span><span style="color: black;">的最新数据，公告<span style="color: black;">说到</span>：I期临床<span style="color: black;">实验</span>3年随访数据<span style="color: black;">表示</span>，接受过癌症疫苗的胰腺导管腺癌</span><span style="color: black;">（PDAC）</span><span style="color: black;"><span style="color: black;">病人</span>三年后仍有免疫反应。</span></span><img src="https://mmbiz.qpic.cn/sz_mmbiz_png/Lkw2iaE07M9Wzr6KRO3f7ex1zWuPgUI7brWYuNayIjTBEUDYZ86eIHXjKWkjMPANyzwpTETShRuibZPdPHywvLvA/640?wx_fmt=png&amp;from=appmsg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;">
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">照片</span><span style="color: black;">源自</span>：BioNtech官网</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">上文<span style="color: black;">说到</span>的癌症疫苗BNT122由BioNTech和罗氏旗下的基因泰克联合<span style="color: black;">研发</span>，是一款个体化新抗原疫苗。<span style="color: black;">制品</span>基于BioNTech的iNeST癌症疫苗技术平台<span style="color: black;">研发</span>，旨在激发人体针对肿瘤细胞产生更为全面的免疫反应，防止肿瘤细胞逃避免疫系统的攻击。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">在<span style="color: black;">这儿</span>简单介绍一下<span style="color: black;">胰腺导管腺癌的<span style="color: black;">状况</span></span>。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">PDAC</span><span style="color: black;">（Pancreatic&nbsp;Ductal&nbsp;Adenocarcinoma，胰腺导管腺癌）</span><span style="color: black;">，一种起源于胰腺导管上皮细胞的恶性肿瘤，约占所有胰腺癌病例的85%<span style="color: black;">上下</span>。<span style="color: black;">疾患</span>特点是<span style="color: black;">发展</span><span style="color: black;">快速</span>，且<span style="color: black;">初期</span>症状不<span style="color: black;">显著</span>。这就<span style="color: black;">引起</span>了这类<span style="color: black;">病人</span>在诊断时<span style="color: black;">常常</span>已<span style="color: black;">处在</span>晚期，治疗<span style="color: black;">选取</span>有限。<span style="color: black;">据说</span>，PDAC<span style="color: black;">病人</span>的五年总体<span style="color: black;">存活</span>率仅为8%-10%，术后复发率接近80%。<span style="color: black;">因此呢</span>，探索更有效的<span style="color: black;">初期</span>诊断<span style="color: black;">办法</span>和新的治疗策略<span style="color: black;">始终</span>是<span style="color: black;">病人</span>和<span style="color: black;">大夫</span>的<span style="color: black;">一起</span>期盼。</span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">此<span style="color: black;">次<span style="color: black;">颁布</span>的3年随访数据<span style="color: black;">重点</span>有以下几个亮点：</span></span></p><span style="color: black;">在16名<span style="color: black;">病人</span>中，有8名<span style="color: black;">病人</span>在接受BNT122治疗后产生了针对编码新抗原的特异性T细胞。</span><span style="color: black;">由BNT122诱导并靶向肿瘤上个体新抗原的98%的T细胞为全新生成，即在治疗前未在血液、肿瘤及邻近组织中检测到这些细胞。</span><span style="color: black;">产生免疫应答的<span style="color: black;">病人</span><span style="color: black;">身体</span>新生成的T细胞中有80%在接种后3年时间内仍可被检测到，相较于<span style="color: black;">没</span>应答者<span style="color: black;">表示</span>出延长的中位<span style="color: black;">没</span>复发<span style="color: black;">存活</span>期。</span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">在三年随访期内，对BNT122产生免疫应答的8名<span style="color: black;">病人</span>中有6名始终保持<span style="color: black;">没</span><span style="color: black;">疾患</span>状态；而对治疗<span style="color: black;">没</span>免疫应答的8名<span style="color: black;">病人</span>中，有7名<span style="color: black;">显现</span>了肿瘤复发的<span style="color: black;">状况</span>。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">以上信息都说明BNT122的确<span style="color: black;">潜能</span>可期。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">BioNtech<span style="color: black;">亦</span><span style="color: black;">暗示</span>其II期临床<span style="color: black;">实验</span>正在美国的多个临床<span style="color: black;">实验</span>点招募<span style="color: black;">病人</span>，<span style="color: black;">将来</span>还计划在<span style="color: black;">全世界</span>范围内增设<span style="color: black;">实验</span>点。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">除了BioNTech，Moderna<span style="color: black;">亦</span>正与默沙东合作<span style="color: black;">研发</span>癌症疫苗mRNA-4157。<span style="color: black;">日前</span>，<span style="color: black;">mRNA-4157</span><span style="color: black;">已然</span>进入III期临床<span style="color: black;">周期</span>，进度上比BioNtech略快一步。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">而以上<span style="color: black;">说到</span>的癌症疫苗均属于治疗性疫苗，<span style="color: black;">重点</span>应用于癌症<span style="color: black;">病人</span>治疗，而非健康人的预防。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">但真正的癌症预防疫苗或许<span style="color: black;">亦</span>不是<span style="color: black;">无</span>可能。就在不久前，牛津大学曾<span style="color: black;">颁布</span><span style="color: black;">信息</span>，<span style="color: black;">叫作</span><span style="color: black;">牛津大学、弗朗西斯·克里克<span style="color: black;">科研</span>所和伦敦大学学院正在<span style="color: black;">科研</span>一款名为“LUNG VAX”的癌症疫苗，并已<span style="color: black;">得到</span></span>&nbsp;170&nbsp;万英镑的<span style="color: black;">开发</span>资金。</span></p><span style="color: black;">参考资料</span><span style="color: black;">1.</span><span style="color: black;">各<span style="color: black;">机构</span>官网</span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">2.Groundbreaking lung cancer vaccine being developed | UK News | Sky News</span></p><span style="color: black;">3.其他公开资料</span><span style="color: black;"><span style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_png/Lkw2iaE07M9VdpWTCkMvY4ibwPdadaqz8TiaC6QUHo2ay416OJfe0eCs0bgZ74JoSIoCm8qJDHeicdictolYDRhandw/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"></span></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;"><span style="color: black;"><span style="color: black;">封面图<span style="color: black;">源自</span>：PIXABAY</span></span></span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">版权声明/免责声明</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">本文为团队原创<span style="color: black;">文案</span>。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">本文仅作信息交流之目的，不<span style="color: black;">供给</span>任何商用、医用、投资用<span style="color: black;">意见</span>。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">文中<span style="color: black;">照片</span>、视频、字体、音乐等素材或为药时代购买的授权正版作品，或来自<span style="color: black;">微X</span>公共<span style="color: black;">照片</span>库，或取自<span style="color: black;">机构</span>官网/网络，部分素材<span style="color: black;">按照</span>CC0协议<span style="color: black;">运用</span>，版权归<span style="color: black;">持有</span>者，药时代尽力注明<span style="color: black;">源自</span>。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">如有任何问题，请与<span style="color: black;">咱们</span>联系。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">衷心感谢!</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">药时代官方<span style="color: black;">网</span>:www.drugtimes.cn</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">联系方式:</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">tel</span>:13651980212</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">微X</span>:27674131</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">邮箱:contact@drugtimes.cn</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/sz_mmbiz_jpg/Lkw2iaE07M9VFEkVlmIib0l9U2nq4f3dOOEOFwCuDQjU5ltMh6QcArsDZicphjrfibQib7zqh9E9ut6JFPh2dFyWsnA/640?wx_fmt=jpeg&amp;from=appmsg&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"></p><a style="color: black;"><span style="color: black;"><img src="https://mmbiz.qpic.cn/sz_mmbiz_jpg/Lkw2iaE07M9UG8bnYDAQa03ATEjYux988I5YKEcdulpY7fr6tYibteUFR4boB8sTIqC9rwRW9bFG5IgFLFNePhgA/640?wx_fmt=jpeg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></span>
      <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">刷新认知！一款ADC的后劲儿能有多大</p>
    </a><a style="color: black;"><span style="color: black;"><img src="https://mmbiz.qpic.cn/sz_mmbiz_jpg/Lkw2iaE07M9XfZ90BqMtbJ5w4QZ59RdYdAXQxRL3ib7SniaZdzTzF7pWjuXyPIk36hxabF96zzuicvNapPoibpqrbpQ/640?wx_fmt=jpeg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></span>
      <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">131亿美元！强生收购又一家心血管器械巨头，3年300亿美元收购，打算重当器械一哥？</p>
    </a><a style="color: black;"><span style="color: black;"><img src="https://mmbiz.qpic.cn/sz_mmbiz_jpg/Lkw2iaE07M9V3CUyks4rDhPmgFFbun2ZNaLRbc4c1J4wNia46n695TmH22kRtmIKIPvjicR814hmtibASemKPOuI1Q/640?wx_fmt=jpeg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></span>
      <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">【药王启示录】K药、司美格鲁肽的故事 | 药时代视频荟萃</p>
    </a><img src="https://mmbiz.qpic.cn/mmbiz_gif/US10Gcd0tQH9Pa6nvdh6CaICF2az6V5pybfOejYGmQAonWMsSLUJGhoyZcv02NIVLMSxvoUf3e6PVsSvibnruxg/640?wx_fmt=gif&amp;wxfrom=5&amp;wx_lazy=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"><span style="color: black;"><strong style="color: blue;">点击阅读原文，<span style="color: black;">认识</span><span style="color: black;">更加多</span>！</strong></span>




情迷布拉格 发表于 2024-8-22 16:03:36

认真阅读了楼主的帖子，非常有益。

7wu1wm0 发表于 2024-10-16 10:28:07

请问、你好、求解、谁知道等。
页: [1]
查看完整版本: 癌症疫苗最新动态：3年后仍存在免疫反应！